Drug Profile

Gefurulimab - Alexion AstraZeneca Rare Disease

Alternative Names: ALXN-1720

Latest Information Update: 19 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alexion AstraZeneca Rare Disease
Class Bispecific antibodies; Recombinant fusion proteins; Single-domain antibodies
Mechanism of Action Complement C5 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Myasthenia gravis
Phase I Proteinuria

Most Recent Events

19 Mar 2025 Alexion AstraZeneca Rare Disease completes the phase I trial (In volunteers) in China (SC) (NCT06677138)
13 Nov 2024 Phase-III clinical trials in Myasthenia gravis (In children, In adolescents) in Taiwan (SC) (NCT06607627)
28 Oct 2024 Alexion AstraZeneca Rare Disease initiates the phase I trial (In volunteers) in China (SC) (NCT06677138)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com